NEW YORK (GenomeWeb) – Molecular diagnostics firm Rosetta Genomics announced today that it will effect a 1-for-12 reverse stock split in order to help regain compliance with the Nasdaq Capital Market's listing requirements.
Registering provides access to this and other free content.
Already have an account?Login Now.
Startup companies are taking on personalized medicine, CNET reports.
Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.
The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.
In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.
This webinar will discuss genomic methods to elucidate the molecular mechanisms underlying acquired resistance to immuno-oncology (IO) therapies.
This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment.
Our roundtable of industry experts will provide an overview of the current regulatory landscape for clinical genomics tests.
In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay.